Welcome to our dedicated page for Fulcrum Therapeutics news (Ticker: FULC), a resource for investors and traders seeking the latest updates and insights on Fulcrum Therapeutics stock.
Fulcrum Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin for the treatment of sickle cell disease, and company updates commonly address PIONEER trial data, markers of hemolysis and anemia, and sickle cell disease collaborations.
FULC news also covers quarterly financial results, corporate presentations, Nasdaq inducement equity grants, board composition, and updates to the company's pipeline and financial position as it advances small molecules that modulate gene expression.
Fulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for July 29, 2025, at 8:00 a.m. ET to present topline results from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
The presentation will feature distinguished speakers including Dr. Sheinei Alan from the Inova Fairfax Adult Sickle Cell Program and Dr. Wally Smith from the VCU Adult Sickle Cell Program, who will join Fulcrum's management team to discuss the findings.
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company awarded 130,000 options at an exercise price of $7.02 per share, matching the closing price on July 7, 2025.
The options, granted under Fulcrum's 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (NASDAQ: FULC) announced upcoming presentations at two major medical conferences: the 5th Global Congress on Sickle Cell Disease in Abuja, Nigeria (June 3-6, 2025) and the 2025 European Hematology Association Congress in Milan, Italy (June 12-15, 2025).
The company will present four posters focusing on Pociredir, their novel oral treatment for Sickle Cell Disease (SCD). The presentations will cover preclinical and early clinical results, Phase 1b trial design, pharmacokinetics and pharmacodynamics in healthy adults, and the drug's mechanism as an EED inhibitor for fetal hemoglobin induction.
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 8:00 am ET in Miami, FL. The presentation will be available via webcast on the company's investor relations website, with replay access for at least 30 days following the event.
Fulcrum Therapeutics (NASDAQ: FULC) has granted stock options to two new employees as part of their inducement compensation package. The grants, made under the company's 2022 Inducement Stock Incentive Plan, include a total of 260,000 options to purchase common stock at an exercise price of $5.73 per share, matching the closing price on May 5, 2025.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. Vesting is contingent on continued employment with Fulcrum through the applicable dates.
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in two upcoming investor conferences in May 2025:
1. The H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York on May 20, 2025
2. The RBC Capital Markets Global Healthcare Conference in New York on May 21, 2025, featuring a fireside chat at 3:35 pm ET
The fireside chat webcast will be available on Fulcrum's investor relations website and will remain accessible for at least 30 days after the presentation.
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has scheduled its first quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. market opening.
The company will host a conference call and webcast at 8:00 a.m. ET where management will present the quarterly results and provide corporate development updates. Participants can access the call through a registration link that will provide dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations website.
Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants, announced on April 11, 2025, include an aggregate of 96,800 options with an exercise price of $2.72 per share, matching the closing price on April 7, 2025.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters, contingent on continued employment.